Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide for Steroid-resistant/dependent Severe cGVHD
NCT05140616Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in chronic graft-versus-host disease (cGVHD), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Number of participants with dose-limiting toxicities at 12 months and Overall Response Rate at 3 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05140616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140616.